Access the full text.
Sign up today, get DeepDyve free for 14 days.
E. Timotheadou, D. Skarlos, E. Samantas, S. Papadopoulos, S. Murray, J. Skřičková, C. Christodoulou, C. Papakostantinou, D. Pectasides, P. Papakostas, J. Kaplanová, E. Vrettou, M. Karina, P. Kosmidis, G. Fountzilas (2007)
Evaluation of the prognostic role of a panel of biomarkers in stage IB-IIIA non-small cell lung cancer patients.Anticancer research, 27 6C
M. Alimandi, A. Romano, M. Curia, R. Muraro, P. Fedi, S. Aaronson, P. Fiore, M. Kraus (1995)
Cooperative signaling of ErbB3 and ErbB2 in neoplastic transformation and human mammary carcinomas.Oncogene, 10 9
A. Marchetti, C. Martella, L. Felicioni, Fabio Barassi, S. Salvatore, A. Chella, P. Camplese, T. Iarussi, F. Mucilli, A. Mezzetti, F. Cuccurullo, R. Sacco, F. Buttitta (2005)
EGFR mutations in non-small-cell lung cancer: analysis of a large series of cases and development of a rapid and sensitive method for diagnostic screening with potential implications on pharmacologic treatment.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 23 4
Norbert Prenzel, O. Fischer, S. Streit, S. Hart, A. Ullrich (2001)
The epidermal growth factor receptor family as a central element for cellular signal transduction and diversification.Endocrine-related cancer, 8 1
T. Dønnem, S. Al-Saad, K. Al-Shibli, M. Delghandi, M. Persson, M. Nilsen, L. Busund, R. Bremnes (2007)
Inverse Prognostic Impact of Angiogenic Marker Expression in Tumor Cells versus Stromal Cells in Non–Small Cell Lung CancerClinical Cancer Research, 13
D. Vallböhmer, J. Brabender, Dongyun Yang, K. Danenberg, P. Schneider, R. Metzger, A. Holscher, P. Danenberg (2006)
Sex differences in the predictive power of the molecular prognostic factor HER2/neu in patients with non-small-cell lung cancer.Clinical lung cancer, 7 5
A. Meert, B. Martin, M. Paesmans, T. Berghmans, C. Mascaux, J. Verdebout, P. Delmotte, J. Lafitte, J. Sculier (2003)
The role of HER-2/neu expression on the survival of patients with lung cancer: a systematic review of the literatureBritish Journal of Cancer, 89
T. Stinchcombe, M. Socinski (2009)
Current treatments for advanced stage non-small cell lung cancer.Proceedings of the American Thoracic Society, 6 2
L. Kunkel, A. Wong, T. Maneatis, J. Nickas, T. Brown, A. Grillo‐López, M. Benyunes, Barry Grobman, R. Dillman (2000)
Optimizing the use of rituximab for treatment of B-cell non-Hodgkin's lymphoma: a benefit-risk update.Seminars in oncology, 27 6 Suppl 12
M. Raso, C. Behrens, M. Herynk, Suyu Liu, L. Prudkin, N. Ozburn, Denise Woods, Ximing Tang, R. Mehran, C. Moran, J. Lee, I. Wistuba (2009)
Immunohistochemical Expression of Estrogen and Progesterone Receptors Identifies a Subset of NSCLCs and Correlates with EGFR MutationClinical Cancer Research, 15
I. Koumakpayi, J. Diallo, C. Page, L. Lessard, M. Gleave, L. Bégin, A. Mes-Masson, F. Saad (2006)
Expression and Nuclear Localization of ErbB3 in Prostate CancerClinical Cancer Research, 12
S. Hobbs, S. Coffing, A. Le, Elizabeth Cameron, Eric Williams, Michelle Andrew, Erika Blommel, R. Hammer, Han Chang, D. Riese (2002)
Neuregulin isoforms exhibit distinct patterns of ErbB family receptor activationOncogene, 21
I. Sekine, M. Sumi, Yoshinori Ito, C. Tanai, H. Nokihara, N. Yamamoto, H. Kunitoh, Y. Ohe, T. Tamura (2009)
Gender difference in treatment outcomes in patients with stage III non-small cell lung cancer receiving concurrent chemoradiotherapy.Japanese journal of clinical oncology, 39 11
M. Cutolo, A. Sulli, C. Craviotto, L. Felli, C. Pizzorni, B. Seriolo, B. Villaggio (2002)
Modulation of Cell Growth and Apoptosis by Sex Hormones in Cultured Monocytic THP‐1 CellsAnnals of the New York Academy of Sciences, 966
N. Dubrawsky (1989)
Cancer statisticsCA: A Cancer Journal for Clinicians, 39
J. Xu, Yu Han, Hai-qing Duan, E. Gao, Yang Zhang, Xiao Liu, Jing Zhang, L. Toschi, D. Galetta, A. Azzariti, A. Paradiso (2009)
EGFR mutations and HER2/3 protein expression and clinical outcome in Chinese advanced non-small cell lung cancer patients treated with gefitinibJournal of Cancer Research and Clinical Oncology, 135
C. Mountain (2000)
The international system for staging lung cancer.Seminars in surgical oncology, 18 2
G. Clamon, J. Herndon, J. Kern, R. Govindan, J. Garst, D. Watson, Mark Green (2005)
Lack of trastuzumab activity in nonsmall cell lung carcinoma with overexpression of erb‐B2Cancer, 103
S. Paik, Chungyeul Kim, Jong-Hyeon Jeong, C. Geyer, E. Romond, O. Mejia-Mejia, E. Mamounas, D. Wickerham, J. Costantino, N. Wolmark (2007)
Benefit from adjuvant trastuzumab may not be confined to patients with IHC 3+ and/or FISH-positive tumors: Central testing results from NSABP B-31Journal of Clinical Oncology, 25
D. Agus, P. Bunn, W. Franklin, M. García, R. Ozols (2000)
HER-2/neu as a therapeutic target in non-small cell lung cancer, prostate cancer, and ovarian cancer.Seminars in oncology, 27 6 Suppl 11
J. Szelachowska, M. Jeleń, J. Kornafel (2006)
Prognostic significance of intracellular laminin and Her2/neu overexpression in non-small cell lung cancer.Anticancer research, 26 5B
P. Grivas, A. Antonacopoulou, V. Tzelepi, G. Sotiropoulou-Bonikou, Z. Kefalopoulou, A. Papavassiliou, H. Kalofonos (2007)
HER-3 in colorectal tumourigenesis: from mRNA levels through protein status to clinicopathologic relationships.European journal of cancer, 43 17
J. Brabender, K. Danenberg, R. Metzger, P. Schneider, Jimin Park, D. Salonga, A. Hölscher, P. Danenberg (2001)
Epidermal growth factor receptor and HER2-neu mRNA expression in non-small cell lung cancer Is correlated with survival.Clinical cancer research : an official journal of the American Association for Cancer Research, 7 7
S. Al-Saad, S. Al-Saad, K. Al-Shibli, T. Dønnem, T. Dønnem, M. Persson, R. Bremnes, R. Bremnes, L. Busund, L. Busund (2008)
The prognostic impact of NF-κB p105, vimentin, E-cadherin and Par6 expression in epithelial and stromal compartment in non-small-cell lung cancerBritish Journal of Cancer, 99
M. Lee, G. Chen, A. Vlantis, G. Tse, B. Leung, C. Hasselt (2005)
Induction of Thyroid Papillary Carcinoma Cell Proliferation by Estrogen Is Associated with an Altered Expression of Bcl‐xLThe Cancer Journal, 11
F. Cappuzzo, L. Bemis, M. Varella-Garcia (2006)
HER2 mutation and response to trastuzumab therapy in non-small-cell lung cancer.The New England journal of medicine, 354 24
E. Tzahar, Y. Yarden (1998)
The ErbB-2/HER2 oncogenic receptor of adenocarcinomas: from orphanhood to multiple stromal ligands.Biochimica et biophysica acta, 1377 1
Antonio Wolff, M. Hammond, Jared Schwartz, K. Hagerty, D. Allred, Richard Cote, M. Dowsett, P. Fitzgibbons, Wedad Hanna, A. Langer, L. McShane, S. Paik, M. Pegram, Edith Perez, Michael Press, A. Rhodes, C. Sturgeon, S. Taube, R. Tubbs, Gail Vance, Marc Vijver, Thomas Wheeler, Daniel Hayes (2006)
American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer.Archives of pathology & laboratory medicine, 131 1
C. Langer, P. Stephenson, A. Thor, M. Vangel, David Johnson (2004)
Trastuzumab in the treatment of advanced non-small-cell lung cancer: is there a role? Focus on Eastern Cooperative Oncology Group study 2598.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 22 7
U. Gatzemeier, G. Groth, C. Butts, N. Zandwijk, F. Shepherd, A. Ardizzoni, C. Barton, P. Ghahramani, V. Hirsh (2004)
Randomized phase II trial of gemcitabine-cisplatin with or without trastuzumab in HER2-positive non-small-cell lung cancer.Annals of oncology : official journal of the European Society for Medical Oncology, 15 1
M. Agarwal, Govinda Brahmanday, G. Chmielewski, R. Welsh, K. Ravikrishnan (2010)
Age, tumor size, type of surgery, and gender predict survival in early stage (stage I and II) non-small cell lung cancer after surgical resection.Lung cancer, 68 3
A. Jemal, R. Siegel, Elizabeth Ward, Y. Hao, Jiaquan Xu, Taylor Murray, M. Thun (2008)
Cancer Statistics, 2008CA: A Cancer Journal for Clinicians, 58
R. Pinkas-Kramarski, L. Soussan, H. Waterman, G. Levkowitz, I. Alroy, L. Klapper, S. Lavi, R. Seger, B. Ratzkin, M. Sela, Y. Yarden (1996)
Diversification of Neu differentiation factor and epidermal growth factor signaling by combinatorial receptor interactions.The EMBO Journal, 15
Haruhiko Nakamura, N. Kawasaki, M. Taguchi, K. Kabasawa (2005)
Association of HER‐2 overexpression with prognosis in nonsmall cell lung carcinoma: A metaanalysisCancer, 103
T. Kosaka, Y. Yatabe, H. Endoh, H. Kuwano, Takashi Takahashi, T. Mitsudomi (2004)
Mutations of the Epidermal Growth Factor Receptor Gene in Lung CancerCancer Research, 64
G. Videtic, C. Reddy, S. Chao, T. Rice, D. Adelstein, G. Barnett, T. Mekhail, M. Vogelbaum, J. Suh (2009)
Gender, race, and survival: a study in non-small-cell lung cancer brain metastases patients utilizing the radiation therapy oncology group recursive partitioning analysis classification.International journal of radiation oncology, biology, physics, 75 4
J. Fijołek, E. Wiatr, Ewa Rowińska-Zakrzewska, D. Giedronowicz, R. Langfort, Mariusz Chabowski, Tadeusz Orlowski, K. Roszkowski (2006)
p53 and HER2/neu Expression in Relation to Chemotherapy Response in Patients with Non-Small Cell Lung CancerThe International Journal of Biological Markers, 21
J. Paez, P. Jänne, Jeffrey Lee, Sean Tracy, H. Greulich, S. Gabriel, P. Herman, F. Kaye, N. Lindeman, T. Boggon, K. Naoki, H. Sasaki, Y. Fujii, M. Eck, W. Sellers, B. Johnson, M. Meyerson (2004)
EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib TherapyScience, 304
R. Rosell (2004)
Toward customized trastuzumab in HER-2/neu-overexpressing non-small-cell lung cancers.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 22 7
T. Takano, T. Fukui, Y. Ohe, K. Tsuta, Seiichiro Yamamoto, H. Nokihara, N. Yamamoto, I. Sekine, H. Kunitoh, K. Furuta, T. Tamura (2008)
EGFR mutations predict survival benefit from gefitinib in patients with advanced lung adenocarcinoma: a historical comparison of patients treated before and after gefitinib approval in Japan.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 26 34
W. Travis, E. Brambilla, H. Müller-hermelink (2004)
Pathology and genetics of tumours of the lung , pleura, thymus and heart
G. Cox, J. Jones, A. Andi, D. Waller, K. O'Byrne (2001)
A biological staging model for operable non-small cell lung cancerThorax, 56
M. Schmitt, K. Klinga, B. Schnarr, R. Morfin, D. Mayer (2001)
Dehydroepiandrosterone stimulates proliferation and gene expression in MCF-7 cells after conversion to estradiolMolecular and Cellular Endocrinology, 173
V. Korrapati, M. Gaffney, L. Larsson, L. Nunno, M. Riggs, R. Beissner, J. Rinehart, F. Mott (2001)
Effect of HER2/neu expression on survival in non-small-cell lung cancer.Clinical lung cancer, 2 3
T. Lynch, D. Bell, Raffaella Sordella, S. Gurubhagavatula, R. Okimoto, Brian Brannigan, Patricia Harris, Sara Haserlat, J. Supko, F. Haluska, D. Louis, D. Christiani, J. Settleman, D. Haber (2004)
Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib.The New England journal of medicine, 350 21
G. Pauletti, Suganda Dandekar, H. Rong, Lilllian Ramos, Hongjun Peng, Ram Seshadri, D. Slamon (2000)
Assessment of methods for tissue-based detection of the HER-2/neu alteration in human breast cancer: a direct comparison of fluorescence in situ hybridization and immunohistochemistry.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 18 21
M. Varella-Garcia, T. Mitsudomi, Y. Yatabe, T. Kosaka, E. Nakajima, A. Xavier, M. Skokan, C. Zeng, W. Franklin, P. Bunn, F. Hirsch (2009)
EGFR and HER2 Genomic Gain in Recurrent Non-small Cell Lung Cancer After Surgery: Impact on Outcome to Treatment with Gefitinib and Association with EGFR and KRAS Mutations in a Japanese CohortJournal of Thoracic Oncology, 4
R. Kancha, N. Bubnoff, C. Peschel, J. Duyster (2009)
Functional Analysis of Epidermal Growth Factor Receptor (EGFR) Mutations and Potential Implications for EGFR Targeted TherapyClinical Cancer Research, 15
A. Koutsopoulos, D. Mavroudis, K. Dambaki, J. Souglakos, E. Tzortzaki, J. Drositis, G. Delides, V. Georgoulias, E. Stathopoulos (2007)
Simultaneous expression of c-erbB-1, c-erbB-2, c-erbB-3 and c-erbB-4 receptors in non-small-cell lung carcinomas: correlation with clinical outcome.Lung cancer, 57 2
Monilola Olayioye, Richard Neve, Heidi Lane, Nancy Hynes (2000)
The ErbB signaling network: receptor heterodimerization in development and cancerThe EMBO Journal, 19
L. Krug, V. Miller, J. Patel, J. Crapanzano, C. Azzoli, Jorge Gomez, M. Kris, R. Heelan, B. Pizzo, L. Tyson, Christine Sheehan, J. Ross, E. Venkatraman (2005)
Randomized phase II study of weekly docetaxel plus trastuzumab versus weekly paclitaxel plus trastuzumab in patients with previously untreated advanced nonsmall cell lung carcinomaCancer, 104
Fred Hirsch, Marileila Varella-Garcia, Wilbur Franklin, R. Veve, L. Chen, B. Helfrich, C. Zeng, Anna Barón, P. Bunn (2002)
Evaluation of HER-2/neu gene amplification and protein expression in non-small cell lung carcinomasBritish Journal of Cancer, 86
Z. Suo, J. Nesland (2002)
Type 1 Protein Tyrosine Kinases in Breast Carcinoma: A ReviewUltrastructural Pathology, 26
ORIGINAL ARTICLE Clinical Significance of Epidermal Growth Factor Receptors in Non-small Cell Lung Cancer and a Prognostic Role for HER2 Gene Copy Number in Female Patients Samer Al-Saad, MD, PhD,*† Khalid Al-Shibli, MD, PhD,*‡ Tom Donnem, MD, PhD,§ Sigve Andersen, MD,§ Roy M. Bremnes, MD,§ and Lill-Tove Busund, MD, PhD*† Key Words: Erb family members, HER2, SISH, Prognosis, Tissue Introduction: To compare the efficacy of silver in situ hybridization microarray, NSCLC. (SISH) and immunohistochemistry (IHC) in detecting HER2 alter- (J Thorac Oncol. 2010;5: 1536–1543) ations and to investigate the prevalence and prognostic significance of Erb family members in non-small cell lung cancer (NSCLC). Methods: Stage I to IIIA tumors from 335 patients with NSCLC olecular factors are gaining ground as prognosticators were immunohistochemically tested for protein expression of all Erb Mand as useful therapeutic targets against lung carci- family members. Membranous HER2 expression was compared noma, the malignancy with the highest mortality. In lung with its gene copy number by SISH in paraffin-embedded, formalin- cancer, the tyrosine kinase Erb family receptors are of great fixed material. Correlations were made with clinicopathological 2– 4 clinical research interest. variables. The human epidermal growth factor receptor (Erb) Results: Synchronous high immunohistochemical expression
Journal of Thoracic Oncology – Wolters Kluwer Health
Published: Oct 1, 2010
Read and print from thousands of top scholarly journals.
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.
To save an article, log in first, or sign up for a DeepDyve account if you don’t already have one.
Copy and paste the desired citation format or use the link below to download a file formatted for EndNote
Access the full text.
Sign up today, get DeepDyve free for 14 days.
All DeepDyve websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.